This webinar will introduce you to the University of Texas System Horizon Fund, a $10 million fund to help commercialize new technologies, inventions and other intellectual property developed at UT system campuses. The fund was established with two goals: (1) Improve commercialization of UT technologies, and (2) Improve sustainability through a positive return on investment.
This webinar will discuss:
- Fund overview: Goals, mission, structure, programs
- Investment strategies: Requirements, criteria, diligence, risk & value assessment
- Faculty relations: how UT works with faculty, educating faculty on startups
- Investor relations: how UT works with outside firms and angel groups
- Better aligning startups with traditional licensing functions of tech transfer
- How UT works with incubators
- Working with students
ABOUT THE PRESENTER:
Bryan Allinson Executive Director University of Texas Horizon Fund University of Texas System
Bryan T. Allinson, Executive Director for Technology Commercialization, serves as the technology commercialization principal at the U.T. System. He directs access to financing and venture capital, entrepreneurial talent and other important resources necessary for commercialization of technology, new ventures and enterprise development; critical pathways for thematic partnering through collaborative activities; and communication of metrics and results, supporting U.T. System and institutional initiatives. Allinson earned dual bachelor of science degrees in chemical engineering and chemistry from the University of Pittsburgh and a master of business administration from Carnegie Mellon University. Prior to his appointment, he served as Director of Technology Transfer at Ohio University. At Ohio, he assisted in monetizing royalty revenue of SOMAVERT®, pharmaceutical product marketed by Pfizer to treat acromegaly, an endrocrine condition affecting more than 40,000 patients worldwide, a deal valued at $52 million. He previously served as Director of Geisinger Ventures, a for-profit division of the Geisinger Health System, where he founded the technology commercialization office. He joined Geisinger in 2005 after serving as the H. J. Heinz Technology Commercialization Fellow at Carnegie Mellon University. Prior to that, he was part of the original team of Agentase, a biotechnology startup company, later acquired by biodefense contractor ICX. Allinson’s commercialization activities range from health, biopharmaceuticals, diagnostics, advanced energy, defense and military, semiconductor, internet. He was previously a board member of the Lewisburg Area School District and Leadership Susquehanna Valley, a Kaufmann Foundation program.